Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer

Published:2014-08 Issue:8 Volume:106 Page:
ISSN:1460-2105
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Prat Aleix,Carey Lisa A.,Adamo Barbara,Vidal Maria,Tabernero Josep,Cortés Javier,Parker Joel S.,Perou Charles M.,Baselga José

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/106/8/dju152/17313383/dju152.pdf

Reference45 articles.

1. Why the epidermal growth factor receptor? The rationale for cancer therapy;Baselga;Oncologist,2002

2. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

3. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease;Cobleigh;J Clin Oncol,1999

4. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2;Slamon;N Engl J Med,2001

5. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer;Piccart-Gebhart;N Engl J Med,2005

Cited by 172 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polymeric nanoparticles as a promising platform for treating triple-negative breast cancer: Current status and future perspectives;International Journal of Pharmaceutics;2024-10

2. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance;Nature Reviews Clinical Oncology;2024-09-13

3. HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial;Clinical Cancer Research;2024-07-12

4. Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer;Scientific Reports;2024-07-11

5. Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review;Journal of Modern Oncology;2024-07-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3